• Earlier this month, Cardinal Health released its 2026 Advanced Therapies Report, outlining how advanced therapies are moving from hospitals into outpatient and community-based care settings.
• The report underscores that safely expanding advanced therapy administration closer to patients’ homes will depend on new partnerships, infrastructure investment, and careful operational planning.
• We’ll now examine how Cardinal Health’s focus on shifting advanced therapies into community sites of care interacts with its existing investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to believe it can turn its scale in pharmaceutical and medical distribution into steady earnings growth while managing thin margins, regulation, and customer concentration. The new Advanced Therapies Report aligns with the shift toward outpatient and community care, but it does not appear to change the key near term catalyst of execution in higher margin specialty and solutions businesses, nor the central risk of continued regulatory and reimbursement pressure.

The company’s recent expansion of Actinium-225 production in Indianapolis is closely tied to advanced and targeted therapies moving closer to patients, reinforcing Cardinal Health’s role in nuclear and precision health. Together with investments in distribution automation and specialty platforms, this build out sits at the heart of the medium term thesis that Cardinal can layer higher value services on top of its core distribution footprint.

Yet while the growth story in community based advanced therapies is appealing, investors also need to be aware of how potential reimbursement changes could...

Cardinal Health's narrative projects $317.2 billion revenue and $2.6 billion earnings by 2029. This requires 9.0% yearly revenue growth and about a $0.9 billion earnings increase from $1.7 billion today.

Uncover how Cardinal Health's forecasts yield a $249.60 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently estimate Cardinal Health’s fair value between US$168 and about US$525 per share, highlighting very different expectations. Against that backdrop, the push into outpatient advanced therapies and related infrastructure could be an important swing factor for how the company’s long term earnings power is ultimately viewed.

Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.